Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for Enhertu

基于DESTINY-Breast06 III期试验，该试验证明了Enhertu具有统计学意义和临床意义的无进展生存获益

If approved, AstraZeneca and Daiichi Sankyo’s Enhertu will be the first HER2-directed therapy and ADC for patients prior to receiving chemotherapy for metastatic breast cancer

如果获得批准，阿斯利康和第一三共的Enhertu将成为第一个在接受转移性乳腺癌化疗之前针对患者的HER2定向治疗和ADC

Enhertu also granted Breakthrough Therapy Designation in the US for this patient population

恩赫图还在美国为这一患者群体授予了突破性治疗称号

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy..

阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）针对Enhertu（曲妥珠单抗-德鲁替康）的补充生物制剂许可证申请（sBLA）已被美国接受并获得优先审查，用于治疗不可切除或转移性HER2低（IHC 1+或IHC 2+/ISH-）或HER2超低（IHC 0膜染色）乳腺癌的成年患者，这些患者根据DESTINY-Breast06 III期试验的阳性结果，在转移性环境中接受了至少一种内分泌治疗，该试验将Enhertu与化疗进行了比较。。

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the first quarter of 2025..

食品和药物管理局（FDA）优先审查药物申请，如果获得批准，将通过证明安全性或有效性改进，预防严重疾病或提高患者依从性，从而显着改善现有选择。。。

Enhertu was also recently granted Breakthrough Therapy Designation (BTD) by the FDA in this setting. BTD accelerates the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need.

在这种情况下，恩赫图最近也被FDA授予突破性治疗称号（BTD）。BTD加速了潜在新药的开发和监管审查，这些新药旨在治疗严重疾病并解决严重未满足的医疗需求。

HR-positive, HER2-negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2-negative, many of these tumours still carry some level of HER2 expression.2 It is estimated that up to 85-90% of tumours historically classified as HR-positive, HER2-negative, may be HER2-low or HER2-ultralow.3,4.

HR阳性，HER2阴性是最常见的乳腺癌亚型，约占所有乳腺癌的70%[1]。尽管被归类为HER2阴性，但其中许多肿瘤仍携带一定程度的HER2表达[2]。据估计，历史上被归类为HR阳性，HER2阴性的肿瘤中，高达85-90%可能是HER2低或HER2超低[3,4]。

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “While endocrine therapies are widely used in the initial treatment of HR-positive metastatic breast cancer, most patients see limited benefit with additional lines of treatment, and subsequent chemotherapy is associated with poor response rates and outcomes.

阿斯利康肿瘤研发执行副总裁苏珊·加尔布雷斯（SusanGalbraith）说：“虽然内分泌治疗广泛用于HR阳性转移性乳腺癌的初始治疗，但大多数患者认为额外治疗方案的益处有限，随后的化疗与不良反应率和结果有关。

The results from DESTINY-Breast06 show that Enhertu has the potential to evolve the current HR-positive treatment landscape and become the first targeted treatment for patients with HER2-low or HER2-ultralow expression following endocrine therapy.”.

DESTINY-Breast06的结果表明，Enhertu有可能发展当前的HR阳性治疗格局，并成为内分泌治疗后HER2低表达或HER2超低表达患者的第一个靶向治疗。”。

Ken Takeshita, Global Head, R&D, Daiichi Sankyo, said: “This Priority Review highlights the potential to expand the existing indication of Enhertu in HER2-low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2-ultralow.

第一三共全球研发主管Ken Takeshita说：“这项优先审查强调了扩大HER2低转移性乳腺癌现有Enhertu适应症的潜力，包括在早期疾病环境以及包括HER2超低在内的更广泛患者人群中使用。

We look forward to working closely with the FDA with the goal of bringing Enhertu to more patients as quickly as possible.”.

我们期待着与FDA密切合作，以尽快将Enhertu带给更多患者。”。

The sBLA is based on data from the DESTINY-Breast06 Phase III trial presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and recently published in The New England Journal of Medicine.

sBLA基于在2024年美国临床肿瘤学会（ASCO）年会上提出的DESTINY-Breast06 III期试验的数据，该试验最近发表在《新英格兰医学杂志》上。

In the trial, Enhertu reduced the risk of disease progression or death by 37% by blinded independent central review (BICR) versus chemotherapy (hazard ratio [HR] 0.63; 95% confidence interval [CI] 0.53-0.75; p<0.0001) in the overall trial population. Median PFS was 13.2 months with Enhertu compared to 8.1 months with chemotherapy..

在该试验中，Enhertu通过盲法独立中央审查（BICR）与化疗（危险比[HR]0.63；95%置信区间[CI]0.53-0.75；p<0.0001）将疾病进展或死亡风险降低了37%。Enhertu的中位PFS为13.2个月，而化疗为8.1个月。。

Results were consistent between patients with HER2-low expression and HER2-ultralow expression. In the primary endpoint analysis of patients with HER2-low expression, Enhertu showed a median PFS of 13.2 months compared to 8.1 months for chemotherapy (HR 0.62; 95% CI 0.51-0.74; p<0.0001). In a prespecified exploratory analysis of patients with HER2-ultralow expression, Enhertu showed a median PFS of 13.2 months versus 8.3 months, respectively (HR 0.78; 95% CI 0.50-1.21)..

HER2低表达和HER2超低表达患者的结果一致。在HER2低表达患者的主要终点分析中，Enhertu显示中位PFS为13.2个月，而化疗为8.1个月（HR 0.62；95%CI 0.51-0.74；p＜0.0001）。在对HER2超低表达患者的预先指定的探索性分析中，Enhertu显示中位PFS分别为13.2个月和8.3个月（HR 0.78；95%CI 0.50-1.21）。。

The safety profile of Enhertu in DESTINY-Breast06 was consistent with previous clinical trials of Enhertu in breast cancer with no new safety concerns identified.

Enhertu在DESTINY-Breast06中的安全性与之前Enhertu在乳腺癌中的临床试验一致，没有发现新的安全性问题。

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Enhertu是由Daiichi Sankyo发现的一种专门设计的HER2定向DXd抗体-药物偶联物（ADC），由AstraZeneca和Daiichi Sankyo联合开发和商业化。

Enhertu is already approved in more than 65 countries, including the US, for patients with HER2-low metastatic breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial..

Enhertu已经在包括美国在内的65多个国家获得批准，用于HER2低转移性乳腺癌患者，这些患者先前在转移性环境中接受过全身治疗，或者根据DESTINY-Breast04试验的结果在完成辅助化疗后的六个月内或六个月内出现疾病复发。。

Notes

注意事项

Breast cancer and HER2 expression

乳腺癌与HER2表达

Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.5 More than two million breast cancer cases were diagnosed in 2022 with more than 665,000 deaths globally.5 While survival rates are high for those diagnosed with early breast cancer, only approximately 30% of patients who are diagnosed with or who progress to metastatic disease are expected to live five years after their diagnosis.1.

乳腺癌是世界上第二大最常见的癌症，也是全球癌症相关死亡的主要原因之一。2022年诊断出200多万例乳腺癌病例，全球死亡人数超过665000人。虽然早期乳腺癌患者的生存率很高，但只有约30%被诊断患有或进展为转移性疾病的患者预计在诊断后五年内存活。

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumours, including breast cancer.6 Patients with high levels of HER2 expression (IHC 3+ or 2+/ISH+) are classified as HER2-positive and treated with HER2-directed therapies, representing approximately 15-20% of all breast cancers.7 Historically, tumours that were not classified as HER2-positive were classified as HER2-negative.2.

HER2是一种酪氨酸激酶受体生长促进蛋白，在包括乳腺癌在内的许多类型的肿瘤表面表达[6]。HER2表达水平高（IHC 3+或2+/ISH+）的患者被归类为HER2阳性，并用HER2指导治疗，约占所有乳腺癌的15-20%.7历史上，未被归类为HER2阳性的肿瘤被归类为HER2阴性。

HR-positive, HER2-negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2-negative, many of these tumours still carry some level of HER2 expression.2 It is estimated that 60-65% of HR-positive, HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultralow.3,4.

HR阳性，HER2阴性是最常见的乳腺癌亚型，约占所有乳腺癌的70%[1]。尽管被归类为HER2阴性，但其中许多肿瘤仍携带一定程度的HER2表达[2]。据估计，60-65%的HR阳性，HER2阴性乳腺癌HER2低，另外25%可能是HER2超低[3,4]。

Endocrine therapies are widely used in the early lines of treatment for HR-positive metastatic breast cancer; however, after two lines of treatment, further efficacy from endocrine therapy is often limited.8 The current standard of care following endocrine therapy is chemotherapy, which is associated with poor response rates and outcomes.8-11.

内分泌治疗广泛用于HR阳性转移性乳腺癌的早期治疗；然而，经过两种治疗方案后，内分泌治疗的进一步疗效往往有限[8]。内分泌治疗后目前的护理标准是化疗，这与不良反应率和预后有关[8-11]。

Prior to the approval of Enhertu in HER2-low metastatic breast cancer post chemotherapy based on the DESTINY-Breast04 trial, there were no targeted therapies approved specifically for patients with HER2-low expression. There are no targeted therapies specifically approved for patients with HER2-low expression prior to chemotherapy or for patients with HER2-ultralow expression.12.

在基于DESTINY-Breast04试验的HER2低转移性乳腺癌化疗后批准Enhertu之前，没有专门针对HER2低表达患者的靶向治疗。没有针对化疗前HER2低表达患者或HER2超低表达患者的靶向治疗。

DESTINY-Breast06

DESTINY-Breast06

DESTINY-Breast06 is a global, randomised, open-label, Phase III trial evaluating the efficacy and safety of Enhertu (5.4mg/kg) versus investigator’s choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) advanced or metastatic breast cancer.

DESTINY-Breast06是一项全球性，随机，开放标签的III期临床试验，评估Enhertu（5.4mg/kg）与研究者选择的化疗（卡培他滨，紫杉醇或nab-紫杉醇）在HR阳性，HER2低（IHC 1+或2+/ISH-）或HER2超低（IHC 0膜染色）晚期或转移性乳腺癌患者中的疗效和安全性。

Patients in the trial had no prior chemotherapy for advanced or metastatic disease and received at least two lines of prior endocrine therapy in the metastatic setting. Patients were also eligible if they had received one prior line of endocrine therapy combined with a CDK4/6 inhibitor in the metastatic setting and experienced disease progression within six months of starting 1st-line treatment or received endocrine therapy as an adjuvant treatment and experienced disease recurrence within 24 months..

试验中的患者之前没有接受过晚期或转移性疾病的化疗，并且在转移性环境中接受了至少两行先前的内分泌治疗。如果患者在转移性环境中接受过一种先前的内分泌治疗联合CDK4/6抑制剂，并且在开始一线治疗的六个月内经历了疾病进展，或者接受了内分泌治疗作为辅助治疗，并且在24个月内经历了疾病复发，则患者也符合条件。。

HER2 status in the trial was confirmed by central laboratory and was performed on an archival tumour sample obtained at the time of initial metastatic diagnosis or later. If archival tissue was not available, a fresh tissue sample was required.

。如果没有档案组织，则需要新鲜的组织样本。

The primary endpoint is PFS in the HR-positive, HER2-low patient population as measured by BICR. Key secondary endpoints include PFS by BICR in the overall trial population (HER2-low and HER2-ultralow), OS in the HER2-low patient population and OS in the overall trial population. Other secondary endpoints include ORR, DOR, time to first subsequent treatment or death, time to second subsequent treatment or death and safety..

主要终点是通过BICR测量的HR阳性，HER2低患者人群中的PFS。关键的次要终点包括BICR在总体试验人群（HER2低和HER2超低）中的PFS，HER2低患者人群中的OS和总体试验人群中的OS。其他次要终点包括ORR，DOR，首次后续治疗或死亡的时间，第二次后续治疗或死亡的时间和安全性。。

DESTINY-Breast06 enrolled 866 patients (n=713 for HER2-low and n=153 for HER2-ultralow) randomised at multiple sites in Asia, Europe, Australia, North America and South America. For more information about the trial, visit ClinicalTrials.gov.

DESTINY-Breast06在亚洲，欧洲，澳大利亚，北美和南美的多个地点随机招募了866名患者（HER2-low n=713，HER2-ultralow n=153）。有关该试验的更多信息，请访问ClinicalTrials.gov。

Enhertu

恩赫蒂

Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers..

Enhertu是HER2定向的ADC。Enhertu采用第一三共专有的DXd ADC技术设计，是第一三共肿瘤学组合中的领先ADC，也是阿斯利康ADC科学平台中最先进的项目。Enhertu由HER2单克隆抗体组成，该抗体通过基于四肽的可切割接头连接到许多拓扑异构酶I抑制剂有效载荷（exatecan衍生物DXd）。。

Enhertu (5.4mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+ or in-situ hybridisation [ISH]+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial..

Enhertu（5.4mg/kg）在全球65多个国家被批准用于治疗不可切除或转移性HER2阳性（免疫组织化学[IHC]3+或原位杂交[ISH]+）乳腺癌的成年患者，这些患者先前在转移性环境或新辅助或辅助环境中接受过抗HER2方案，并且根据DESTINY-Breast03试验的结果，在完成治疗后的六个月内或六个月内出现疾病复发。。

Enhertu (5.4mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial..

Enhertu（5.4mg/kg）已在全球65多个国家获得批准，用于治疗无法切除或转移性HER2-low（IHC 1+或IHC 2+/ISH-）乳腺癌的成年患者，这些患者先前在转移性环境中接受过全身治疗，或者根据DESTINY-Breast04试验的结果，在完成辅助化疗后的六个月内或六个月内出现疾病复发。。

Enhertu (5.4mg/kg) is approved in more than 45 countries worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumours have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials.

Enhertu（5.4mg/kg）在全球45多个国家被批准用于治疗无法切除或转移性NSCLC的成年患者，这些患者的肿瘤具有激活的HER2（ERBB2）突变，如通过当地或地区批准的测试所检测到的，并且已经根据DESTINY-Lung02和/或DESTINY-Lung05试验的结果接受了先前的全身治疗。

Continued approval in the US for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial..

美国对该适应症的持续批准可能取决于验证性试验中临床益处的验证和描述。。

Enhertu (6.4mg/kg) is approved in more than 45 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric06 trials.

Enhertu（6.4mg/kg）在全球超过45个国家被批准用于治疗局部晚期或转移性HER2阳性（IHC 3+或2+/ISH+）胃或胃食管交界处（GEJ）腺癌的成年患者，这些患者已经接受了基于DESTINY-Gastric01，DESTINY-Gastric02和/或DESTINY-Gastric06试验结果的先前基于曲妥珠单抗的方案。

Full approval in China for this indication will depend on whether a randomised controlled confirmatory clinical trial can demonstrate clinical benefit in this population..

中国对该适应症的完全批准将取决于随机对照验证性临床试验是否可以证明该人群的临床益处。。

Enhertu (5.4mg/kg) is approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 trials.

Enhertu（5.4mg/kg）在美国被批准用于治疗无法切除或转移性HER2阳性（IHC 3+）实体瘤的成年患者，这些患者先前接受过全身治疗，并且根据DESTINY-PanTumor02，DESTINY-Lung01和DESTINY-CRC02试验的疗效结果没有令人满意的替代治疗选择。

Continued approval for this indication in the US may be contingent upon verification and description of clinical benefit in a confirmatory trial..

在美国继续批准该适应症可能取决于验证性试验中临床益处的验证和描述。。

Enhertu development programme

恩赫图发展计划

A comprehensive global clinical development programme is underway evaluating the efficacy and safety of Enhertu monotherapy across multiple HER2-targetable cancers. Trials in combination with other anti-cancer treatments, such as immunotherapy, also are underway.

一项全面的全球临床开发计划正在评估Enhertu单药治疗多种HER2靶向癌症的疗效和安全性。与免疫疗法等其他抗癌治疗相结合的试验也正在进行中。

Daiichi Sankyo collaboration

第一三共合作

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and datopotamab deruxtecan..

阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）于2019年3月达成全球合作，共同开发Enhertu，并于2020年7月将其商业化，但在日本，第一三共（Daiichi Sankyo）对每个ADC拥有专有权。Daiichi Sankyo负责Enhertu和datopotamab deruxtecan的制造和供应。。

AstraZeneca in breast cancer

阿斯利康治疗乳腺癌

Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death..

在对乳腺癌生物学越来越了解的推动下，阿斯利康开始挑战并重新定义当前乳腺癌分类和治疗的临床范例，以便为有需要的患者提供更有效的治疗方法-大胆的目标是有朝一日消除乳腺癌作为死亡原因。。

AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment.

阿斯利康正在开发一系列经过批准且有前途的化合物，这些化合物利用不同的作用机制来解决生物学上多样化的乳腺癌肿瘤环境。

With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings..

通过HER2定向抗体-药物偶联物（ADC）Enhertu（曲妥珠单抗-德鲁替康），阿斯利康和第一三共旨在改善先前治疗的HER2阳性和HER2低转移性乳腺癌的预后，并正在探索其在早期治疗和新乳腺癌环境中的潜力。。

In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex and Zoladex (goserelin) and aims to reshape the HR-positive space with first-in-class AKT inhibitor, Truqap, and next-generation SERD and potential new medicine camizestrant. AstraZeneca is also collaborating with Daiichi Sankyo to explore the potential of TROP2-directed ADC, datopotamab deruxtecan, in this setting..

在HR阳性乳腺癌中，阿斯利康继续使用基础药物Faslodex和Zoladex（戈舍瑞林）改善预后，旨在用一流的AKT抑制剂Truqap和下一代SERD以及潜在的新药卡米西坦重塑HR阳性空间。阿斯利康还与第一三共合作，在这种情况下探索TROP2指导的ADC datopotamab deruxtecan的潜力。。

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research Lynparza in these settings and to explore its potential in earlier disease..

PARP抑制剂Lynparza（olaparib）是一种靶向治疗选择，已在具有遗传性BRCA突变的早期和转移性乳腺癌患者中进行了研究。阿斯利康与MSD（美国和加拿大的默克公司）继续在这些环境中研究林帕扎，并探索其在早期疾病中的潜力。。

To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is evaluating the potential of datopotamab deruxtecan alone and in combination with immunotherapy Imfinzi (durvalumab), Truqap in combination with chemotherapy, and Imfinzi in combination with other oncology medicines, including Lynparza and Enhertu..

为了给三阴性乳腺癌（一种侵袭性乳腺癌）患者带来急需的治疗选择，阿斯利康正在评估达托单抗-德鲁替康单独和联合免疫治疗Imfinzi（durvalumab），Truqap联合化疗以及Imfinzi联合其他肿瘤药物（包括Lynparza和Enhertu）的潜力。。

AstraZeneca in oncology

阿斯利康肿瘤学

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

阿斯利康（AstraZeneca）正在领导一场肿瘤学革命，致力于为各种形式的癌症提供治疗，遵循科学理解癌症及其复杂性，发现、开发并向患者提供改变生命的药物。

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

该公司专注于一些最具挑战性的癌症。。

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

阿斯利康的愿景是重新定义癌症护理，并有一天消除癌症作为死亡原因。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢以及呼吸和免疫学）处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. .

。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。。

Contacts

联系人

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

有关如何联系投资者关系团队的详细信息，请单击此处。有关媒体联系人，请单击此处。

References

参考文献

National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed September 2024.

国家癌症研究所。监测、流行病学和最终结果计划。网址：https://seer.cancer.gov/statfacts/html/breast-subtypes.html.2024年9月访问。

Sajjadi E, et al. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist. 2022;5(4):882-888.

Sajjadi E等人。提高HER2低乳腺癌HER2检测的可重复性。抗癌药物抵抗。2022年；5（4）：882-888。

Denkert C, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161.

Denkert C等人。HER2低阳性乳腺癌的临床和分子特征：来自四项前瞻性新辅助临床试验的个体患者数据的汇总分析。柳叶刀Oncol。2021年8月；22（8）：1151-1161。

Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323.

Chen Z等人，HER2超低乳腺癌与HER2无效或HER2低乳腺癌不同吗？对1363名患者的研究。乳腺癌Res治疗。2023年11月；202（2）：313-323。

Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4. doi: 10.3322/caac.21834.

Bray F等人，《2022年全球癌症统计：GLOBOCAN对185个国家36种癌症的全球发病率和死亡率的估计》。。2024年4月4日。doi:10.3322/caac.21834。

Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;852748.

Iqbal N等人。癌症中的人表皮生长因子受体2（HER2）：过表达和治疗意义。摩尔生物国际2014；852748

Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34-44.

Ahn S等。乳腺癌中HER2的状态：指南的变化和解释的复杂因素。J Pathol Transl Med。2020；54（1）：34-44。

Manohar P, et al. Updates in endocrine therapy for metastatic breast cancer. Cancer Biol Med. 2022 Feb 15; 19(2):202–212.

Manohar P等人。转移性乳腺癌内分泌治疗的最新进展。癌症生物学杂志2022年2月15日；19（2）：202-212。

Cortes J, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-923.

Cortes J等人。Eribulin单药治疗与转移性乳腺癌患者的医生选择治疗（拥抱）：一项3期开放标签随机研究。柳叶刀。2011年；377:914-923年。

Yuan P, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019;112:57–65.

Yuan P等人。甲磺酸依立布林与长春瑞滨治疗局部复发或转移性乳腺癌的随机临床试验。Eur J癌症。2019年；112:57-65。

Jerusalem G, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncol. 2018;4(10):1367–1374.

耶路撒冷G等人。依维莫司联合依西美坦与依维莫司或卡培他滨单药治疗雌激素受体阳性，HER2阴性的晚期乳腺癌。JAMA Oncol。2018年；4（10）：1367-1374。

Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9-20.

Modi S等人。曲妥珠单抗-德鲁替康在先前治疗的HER2低晚期乳腺癌中的应用。英格兰医学杂志2022；387:9-20。